Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|NWU2015-06-04||CLO-Northwestern University||Phase IIB trial of neoadjuvant oral tamoxifen versus transdermal 4-hydroxytamoxifen in women with DCIS of the breast||Cancer Prevention and Control CIRB||Available to Open|
|NWU2016-08-02||CLO-Northwestern University||A Phase I Single-Arm, Multicenter Pilot Study Aimed at Validating Gamma-OHPdG as a Biomarker and Testing the Effects of Polyphenon E® on its Levels in Patients with Cirrhosis||Cancer Prevention and Control CIRB||Available to Open|
|NWU2017-09-01||CLO-Northwestern University||Phase I trial of endoxifen gel versus placebo gel in women undergoing breast surgery||Cancer Prevention and Control CIRB||Available to Open|
|PACCT-1||ECOG||Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial||Adult CIRB - Late Phase Emphasis||Available to Open|
|PBTC-049||PBTC||A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Primary CNS Tumors||Pediatric CIRB||Available to Open|
|PBTC-049||PBTC||A Pediatric Brain Tumor Consortium Phase I/II and Surgical Study of CX-4945 in Patients with Recurrent SHH Medulloblastoma||Pediatric CIRB||Available to Open|
|PBTC-051||PBTC||Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects with Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma||Pediatric CIRB||Available to Open|
|PBTC-053||PBTC||A Pediatric Brain Tumor Consortium Phase I/II and Surgical Study of CX-4945 in Patients with Recurrent SHH Medulloblastoma||Pediatric CIRB||Available to Open|
|PBTC-055||PBTC||Phase I/II trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF fusion/duplication positive or NF1-associated recurrent or progressive gliomas in children and young adults||Pediatric CIRB||Available to Open|
|PBTC-056||PBTC||A Phase I study of the ADAM-10 inhibitor, INCB7839 in children with recurrent/progressive high-grade gliomas to target microenvironmental neuroligin-3||Pediatric CIRB||Available to Open|